Literature DB >> 31010461

Idiopathic Pulmonary Fibrosis: Epidemiology, Diagnosis andOutcomes.

Yosafe Wakwaya1, Kevin K Brown2.   

Abstract

The incidence and prevalence of idiopathic pulmonary fibrosis (IPF) is increasing worldwide. This, combined with its poor prognosis and unpredictable natural history, has amplified the importance of an accurate diagnosis and monitoring. A diagnosis of exclusion, IPF requires a comprehensive clinical evaluation. This results in a clinical context that provides the backdrop for interpretation of the chest imaging and histopathology. A confident or probable usual interstitial pneumonia chest imaging pattern on high-resolution computerized tomography may be diagnostic in the correct clinical context. Outcomes for IPF are unpredictable, ranging from rapid progression with death within months to prolonged stability. Disease activity is monitored by clinical and physiology measures with a declining forced vital capacity, a recognized measure of progression. The available treatments, pirfenidone and nintedanib, are effective at reducing the expected decline in forced vital capacity.
Copyright © 2019 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Idiopathic pulmonary fibrosis; Natural history; Outcome

Year:  2019        PMID: 31010461     DOI: 10.1016/j.amjms.2019.02.013

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  13 in total

1.  Clinical efficacy and quality of life effect of acetylcysteine plus pirfenidone in patients with pulmonary fibrosis.

Authors:  Rong Zhang; Zhanshuai Song; Yan Guan; Juan Zhang; Jianfang Zou; Yingxin Sun; Hua Shao
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

2.  Inflammatory bowel disease and risk of idiopathic pulmonary fibrosis: A protocol for systematic review and meta-analysis.

Authors:  Jiali Wang; Fushun Kou; Xiao Han; Lei Shi; Rui Shi; Zhibin Wang; Tangyou Mao; Junxiang Li
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

3.  [Differential mRNA expression in C57BL/6 mice with bleomycin-induced pulmonary fibrosis and its association with LncRNA co-expression network].

Authors:  Xuefei Yu; Li Li; Linxin Zheng; Weifeng Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-01-30

Review 4.  TGF‑β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review).

Authors:  Zhimin Ye; Yongbin Hu
Journal:  Int J Mol Med       Date:  2021-05-20       Impact factor: 4.101

Review 5.  Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis.

Authors:  Mahbub Hasan; Nidhan Chandra Paul; Shamrat Kumar Paul; Abu Saim Mohammad Saikat; Hafeza Akter; Manoj Mandal; Sang-Suk Lee
Journal:  Molecules       Date:  2022-02-22       Impact factor: 4.411

Review 6.  The Role of Extracellular Vesicles in Idiopathic Pulmonary Fibrosis Progression: An Approach on Their Therapeutics Potential.

Authors:  Alma Aurora Ramírez-Hernández; Juan Manuel Velázquez-Enríquez; Jovito Cesar Santos-Álvarez; Armando López-Martínez; Edilburga Reyes-Jiménez; Gabriela Carrasco-Torres; Karina González-García; Verónica Rocío Vásquez-Garzón; Rafael Baltierrez-Hoyos
Journal:  Cells       Date:  2022-02-11       Impact factor: 6.600

7.  Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial.

Authors:  Arantza Campo; José María González-Ruiz; Enrique Andreu; Ana B Alcaide; María M Ocón; Juan De-Torres; Jesús Pueyo; Rosa Cordovilla; Eva Villaron; Fermín Sanchez-Guijo; Miguel Barrueco; Jorge Nuñez-Córdoba; Felipe Prósper; Javier J Zulueta
Journal:  ERJ Open Res       Date:  2021-06-28

8.  Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Wharton's jelly.

Authors:  Kuo-An Chu; Shih-Yao Wang; Chang-Ching Yeh; Tz-Win Fu; Yu-Yi Fu; Tsui-Ling Ko; Mei-Miao Chiu; Tien-Hua Chen; Pei-Jiun Tsai; Yu-Show Fu
Journal:  Theranostics       Date:  2019-09-17       Impact factor: 11.556

9.  Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a prospective, multicentre registry study.

Authors:  Bingbing Xie; Yanhong Ren; Jing Geng; Xuan He; Chengjun Ban; Shiyao Wang; Dingyuan Jiang; Sa Luo; Qihang Chen; Min Liu; Ruie Feng; Ling Zhao; Huaping Dai; Chen Wang
Journal:  BMJ Open       Date:  2020-11-11       Impact factor: 2.692

10.  Characterization of the heterogeneity of endothelial cells in bleomycin-induced lung fibrosis using single-cell RNA sequencing.

Authors:  Xiucheng Liu; Xichun Qin; Hao Qin; Caili Jia; Yanliang Yuan; Teng Sun; Bi Chen; Chang Chen; Hao Zhang
Journal:  Angiogenesis       Date:  2021-05-24       Impact factor: 9.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.